Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
DSGN Design Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: DSGN
Price (delayed)
$3.52
Market cap
$199.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.99
Enterprise value
$187.48M
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on
Highlights
DSGN's debt is down by 38% year-on-year and by 14% since the previous quarter
DSGN's net income is down by 13% QoQ but it is up by 4.2% YoY
The EPS has declined by 13% since the previous quarter but it rose by 6% year-on-year
The quick ratio has contracted by 27% YoY and by 3.9% from the previous quarter
Design Therapeutics's equity has decreased by 15% YoY and by 6% QoQ
Key stats
What are the main financial stats of DSGN
Market
Valuations
Earnings
Shares outstanding
56.77M
Market cap
$199.83M
Enterprise value
$187.48M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.88
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$68.4M
Net income
-$56.2M
EBIT
-$56.2M
EBITDA
-$55.59M
Free cash flow
-$47.67M
Per share
Balance sheet
Liquidity
EPS
-$0.99
EPS diluted
-$0.99
Free cash flow per share
-$0.84
Book value per share
$4.02
Revenue per share
$0
TBVPS
$4.18
Total assets
$237.48M
Total liabilities
$9.56M
Debt
$1.32M
Equity
$227.92M
Working capital
$225.41M
Debt to equity
0.01
Current ratio
28.37
Quick ratio
27.89
Net debt/EBITDA
0.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-22%
Return on equity
-22.9%
Return on invested capital
-25.4%
Return on capital employed
-24.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DSGN stock price
How has the Design Therapeutics stock price performed over time
Intraday
5.71%
1 week
-25.27%
1 month
19.32%
1 year
-24.95%
YTD
-42.95%
QTD
-8.81%
Financial performance
How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$68.4M
Net income
-$56.2M
Gross margin
N/A
Net margin
N/A
DSGN's net income is down by 13% QoQ but it is up by 4.2% YoY
DSGN's operating income is down by 10% since the previous quarter but it is up by 3.6% year-on-year
Price vs fundamentals
How does DSGN's price correlate with its fundamentals
Growth
What is Design Therapeutics's growth rate over time
Valuation
What is Design Therapeutics stock price valuation
P/E
N/A
P/B
0.88
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has declined by 13% since the previous quarter but it rose by 6% year-on-year
DSGN's P/B is 48% below its 5-year quarterly average of 1.7 and 20% below its last 4 quarters average of 1.1
Design Therapeutics's equity has decreased by 15% YoY and by 6% QoQ
Efficiency
How efficient is Design Therapeutics business performance
DSGN's ROE is down by 19% QoQ and by 10% YoY
Design Therapeutics's ROA has decreased by 18% from the previous quarter and by 11% YoY
The company's return on invested capital fell by 17% QoQ and by 13% YoY
Dividends
What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DSGN.
Financial health
How did Design Therapeutics financials performed over time
DSGN's current ratio is down by 27% year-on-year and by 3.2% since the previous quarter
The quick ratio has contracted by 27% YoY and by 3.9% from the previous quarter
DSGN's debt is 99% smaller than its equity
DSGN's debt is down by 38% year-on-year and by 14% since the previous quarter
Design Therapeutics's equity has decreased by 15% YoY and by 6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.